{"id":9520,"date":"2026-02-24T10:21:47","date_gmt":"2026-02-24T15:21:47","guid":{"rendered":"https:\/\/www.curingheartdisease.com\/?p=9520"},"modified":"2026-07-16T10:53:18","modified_gmt":"2026-07-16T14:53:18","slug":"el-avance-del-colesterol-de-las-pastillas-diarias-a-las-inyecciones-dos-veces-al-ano","status":"publish","type":"post","link":"https:\/\/www.curingheartdisease.com\/es\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/","title":{"rendered":"El avance del colesterol: de las pastillas diarias a las inyecciones semestrales"},"content":{"rendered":"

Abstract<\/h3>\n

Atherosclerotic cardiovascular disease (ASCVD) remains the leading global cause of mortality despite major advances in acute care. Modern preventive cardiology increasingly recognizes apolipoprotein B (ApoB)\u2013containing lipoproteins as the necessary and causal drivers of atherosclerosis. Evidence from genetics, epidemiology, and randomized trials supports a cumulative exposure model in which the magnitude and duration of ApoB exposure determine lifetime risk. This review synthesizes foundational biological discoveries, landmark clinical trials, Mendelian randomization studies, and emerging gene-based therapies that collectively define a shift from reactive treatment to primordial prevention.
\n\"\"<\/p>\n

    \n
  1. \n

    The Modern Prevention Paradigm<\/h3>\n<\/li>\n<\/ol>\n

    Although mortality from acute myocardial infarction has declined substantially, the global burden of ASCVD remains high due to persistent exposure to modifiable risk factors. The PURE study demonstrated that traditional risk factors account for the majority of cardiovascular events across diverse global populations [1].<\/p>\n

    Preventive cardiology is therefore shifting from treating late-stage events to preventing plaque formation altogether\u2014a strategy consistent with the concept of primordial prevention.<\/p>\n

      \n
    1. \n

      LDL Receptors and the Central Role of ApoB<\/h3>\n<\/li>\n<\/ol>\n

      The biological foundation of lipid-lowering therapy rests on the LDL receptor (LDLR) pathway described by Brown and Goldstein [2]. Hepatic LDLR expression increases clearance of circulating ApoB-containing particles (LDL, VLDL remnants, Lp(a)), thereby reducing atherogenic burden.<\/p>\n

      Statins inhibit HMG-CoA reductase, upregulating LDLR expression. PCSK9 inhibitors prevent LDLR degradation, prolonging receptor recycling. In the FOURIER trial, evolocumab reduced LDL-C by approximately 59% and significantly lowered major cardiovascular events [3]. These results reinforced the principle that greater ApoB reduction yields greater cardiovascular risk reduction.<\/p>\n

        \n
      1. \n

        ApoB as the Causal Particle: The Cumulative Exposure Model<\/h3>\n<\/li>\n<\/ol>\n

        The European Atherosclerosis Society consensus statement led by Ference et al. established that ApoB-containing lipoproteins are causal in ASCVD [4]. The total number of circulating atherogenic particles\u2014not LDL-C concentration alone\u2014determines arterial exposure.<\/p>\n

        Genetic, epidemiologic, and clinical trial data support a cumulative burden model (\u201ccholesterol-years\u201d concept):
        \nRisk \u2248 magnitude of ApoB \u00d7 duration of exposure<\/strong>.<\/p>\n

        Short-term 10-year risk calculators may underestimate lifetime risk in younger individuals with prolonged exposure ahead of them. The clinical rationale for ApoB measurement as a more accurate representation of atherogenic particle number has been articulated in detail by Sniderman et al. [5].<\/p>\n

          \n
        1. \n

          Reassessing HDL: Why Raising HDL Failed<\/h3>\n<\/li>\n<\/ol>\n

          Pharmacologic HDL raising has repeatedly failed to reduce cardiovascular events when ApoB burden remains unchanged.<\/p>\n

          The AIM-HIGH trial demonstrated no incremental benefit from adding niacin to intensive statin therapy [6]. The HPS2-THRIVE trial similarly showed no meaningful reduction in major vascular events and identified increased adverse events with niacin therapy [7].<\/p>\n

          These trials shifted focus away from HDL-C as a therapeutic target and reinforced ApoB reduction as the primary modifiable driver of ASCVD risk.<\/p>\n

            \n
          1. \n

            Bempedoic Acid: Upstream LDLR Modulation<\/h3>\n<\/li>\n<\/ol>\n

            Bempedoic acid inhibits ATP-citrate lyase (ACL), an upstream enzyme in cholesterol synthesis. It is activated primarily in the liver and not in skeletal muscle, limiting muscle exposure to the active drug.<\/p>\n

            In the CLEAR Outcomes trial, bempedoic acid reduced major adverse cardiovascular events in statin-intolerant patients [8]. While muscle-related side effects were not significantly increased versus placebo, higher rates of hyperuricemia and gout were observed [8]. Bempedoic acid therefore represents an additional LDLR-mediated strategy for ApoB reduction with a distinct safety profile.<\/p>\n

              \n
            1. \n

              Genetics as a Natural Randomized Trial<\/h3>\n<\/li>\n<\/ol>\n

              Mendelian randomization studies provide insight into lifelong LDL\/ApoB exposure. Ference et al. demonstrated that lifelong genetically lower LDL-C is associated with substantially greater reductions in coronary heart disease risk than those observed in short-term pharmacologic trials [9].<\/p>\n

              The magnitude of benefit per 1 mmol\/L lower LDL-C from birth exceeded the risk reductions typically observed in 5-year statin trials, supporting the principle that earlier and longer ApoB reduction produces larger lifetime benefit [9].<\/p>\n

                \n
              1. \n

                RNA Therapeutics and Gene Editing<\/h3>\n<\/li>\n<\/ol>\n

                PCSK9 siRNA (Inclisiran)<\/strong><\/p>\n

                Inclisiran uses small interfering RNA (siRNA) to inhibit hepatic PCSK9 production. In ORION-1 and subsequent phase 3 trials, inclisiran produced durable LDL-C reductions of approximately 50% with maintenance dosing every six months following initial and 3-month doses [10,11].<\/p>\n

                CRISPR Base Editing (PCSK9)<\/strong><\/p>\n

                In primate studies, in vivo CRISPR base editing of PCSK9 resulted in durable LDL-C reductions [12]. This foundational work forms the scientific basis for first-in-human gene-editing trials such as heart-1 (Verve-101), which aim to achieve long-term reduction of ApoB-containing particles through a single intervention [12].<\/p>\n

                  \n
                1. Comparison of Modern Lipid-Lowering Strategies<\/strong><\/li>\n<\/ol>\n\n\n\n\n\n\n\n\n\n
                  Therapy<\/strong><\/td>\nDosing Frequency<\/strong><\/td>\nPrimary Mechanism<\/strong><\/td>\nKey Evidence<\/strong><\/td>\n<\/tr>\n<\/thead>\n
                  Statins<\/td>\nDaily<\/td>\nHMG-CoA reductase inhibition \u2192 \u2191 LDLR<\/td>\nLandmark statin trials<\/td>\n<\/tr>\n
                  PCSK9 mAbs<\/td>\nEvery 2\u20134 weeks<\/td>\nPrevent LDLR degradation<\/td>\nFOURIER [3]<\/td>\n<\/tr>\n
                  Bempedoic Acid<\/td>\nDaily<\/td>\nACL inhibition (hepatic activation)<\/td>\nCLEAR Outcomes [8]<\/td>\n<\/tr>\n
                  Inclisiran<\/td>\nDay 1, 3 months, then every 6 months<\/td>\nsiRNA blocking PCSK9 production<\/td>\nORION-1, ORION-10\/11 [10,11]<\/td>\n<\/tr>\n
                  PCSK9 Base Editing<\/td>\nInvestigational<\/td>\nPermanent gene editing<\/td>\nPrimate data [12]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

                  References<\/h3>\n
                    \n
                  1. Yusuf S, Joseph P, Rangarajan S, et al. Modifiable risk factors, cardiovascular disease, and mortality in 155\u2008722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study.\u00a0Lancet<\/i>. 2020;395(10226):795-808. doi:10.1016\/S0140-6736(19)32008-2<\/li>\n
                  2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis.\u00a0Science<\/i>. 1986;232(4746):34-47. doi:10.1126\/science.3513311<\/li>\n
                  3. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.\u00a0N Engl J Med<\/i>. 2017;376(18):1713-1722. doi:10.1056\/NEJMoa1615664<\/li>\n
                  4. Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.\u00a0Eur Heart J<\/i>. 2017;38(32):2459-2472. doi:10.1093\/eurheartj\/ehx144<\/li>\n
                  5. Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.\u00a0JAMA Cardiol<\/i>. 2019;4(12):1287-1295. doi:10.1001\/jamacardio.2019.3780<\/li>\n
                  6. AIM-HIGH Investigators, Boden WE, Probstfield JL, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.\u00a0N Engl J Med<\/i>. 2011;365(24):2255-2267. doi:10.1056\/NEJMoa1107579<\/li>\n
                  7. HPS2-THRIVE Collaborative Group, Landray MJ, Haynes R, et al. Effects of extended-release niacin with laropiprant in high-risk patients.\u00a0N Engl J Med<\/i>. 2014;371(3):203-212. doi:10.1056\/NEJMoa1300955<\/li>\n
                  8. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.\u00a0N Engl J Med<\/i>. 2023;388(15):1353-1364. doi:10.1056\/NEJMoa2215024<\/li>\n
                  9. Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis.\u00a0J Am Coll Cardiol<\/i>. 2012;60(25):2631-2639. doi:10.1016\/j.jacc.2012.09.017<\/li>\n
                  10. Ray KK, Landmesser U, Leiter LA, et al. Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.\u00a0N Engl J Med<\/i>. 2017;376(15):1430-1440. doi:10.1056\/NEJMoa1615758<\/li>\n
                  11. Ray KK, Wright RS, Kallend D, et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.\u00a0N Engl J Med<\/i>. 2020;382(16):1507-1519. doi:10.1056\/NEJMoa1912387<\/li>\n
                  12. \u00a0<\/span><\/span>Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates.\u00a0Nature<\/i>. 2021;593(7859):429-434. doi:10.1038\/s41586-021-03534-y<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

                    La enfermedad cardiovascular ateroscler\u00f3tica (ECVA) sigue siendo la principal causa mundial de mortalidad a pesar de los importantes avances en la atenci\u00f3n aguda. La cardiolog\u00eda preventiva moderna reconoce cada vez m\u00e1s a las lipoprote\u00ednas que contienen apolipoprote\u00edna B (ApoB) como los impulsores necesarios y causales de la aterosclerosis.<\/p>","protected":false},"author":16,"featured_media":9532,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[219,220,223,224],"tags":[],"class_list":["post-9520","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lipids-medications-and-testing","category-medications-and-treatments","category-plaque-arteries-and-disease","category-regression-and-reversal"],"acf":[],"yoast_head":"\nThe Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots - The Premiere Heart Health Education Platform<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.curingheartdisease.com\/es\/el-avance-del-colesterol-de-las-pastillas-diarias-a-las-inyecciones-dos-veces-al-ano\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots - The Premiere Heart Health Education Platform\" \/>\n<meta property=\"og:description\" content=\"Atherosclerotic cardiovascular disease (ASCVD) remains the leading global cause of mortality despite major advances in acute care. Modern preventive cardiology increasingly recognizes apolipoprotein B (ApoB)\u2013containing lipoproteins as the necessary and causal drivers of atherosclerosis.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.curingheartdisease.com\/es\/el-avance-del-colesterol-de-las-pastillas-diarias-a-las-inyecciones-dos-veces-al-ano\/\" \/>\n<meta property=\"og:site_name\" content=\"The Premiere Heart Health Education Platform\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/curingheartdisease\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-24T15:21:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T14:53:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Peter Megdal PhD\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:site\" content=\"@RMHDInc\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Peter Megdal PhD\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/\"},\"author\":{\"name\":\"Peter Megdal PhD\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\"},\"headline\":\"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots\",\"datePublished\":\"2026-02-24T15:21:47+00:00\",\"dateModified\":\"2026-07-16T14:53:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/\"},\"wordCount\":1075,\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-34.jpg\",\"articleSection\":[\"Lipids, Medications and Testing\",\"Medications and Treatments\",\"Plaque, Arteries and Disease\",\"Regression and Reversal\"],\"inLanguage\":\"es-AR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/\",\"name\":\"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots - The Premiere Heart Health Education Platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-34.jpg\",\"datePublished\":\"2026-02-24T15:21:47+00:00\",\"dateModified\":\"2026-07-16T14:53:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#breadcrumb\"},\"inLanguage\":\"es-AR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-34.jpg\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/post-image-34.jpg\",\"width\":1200,\"height\":630},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#website\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"name\":\"The Premiere Heart Health Education Platform\",\"description\":\"To make available to the public the state of the art information on how to reverse heart disease. This is an evidence-based organization utilizing the best available science, including diet, exercise drugs, and other resources to best fight this disease.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.curingheartdisease.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-AR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\",\"name\":\"Curing Heart Disease, LLC\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-AR\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"contentUrl\":\"https:\\\/\\\/www.curingheartdisease.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/cropped-Curing-Heart-icon-red.png\",\"width\":512,\"height\":512,\"caption\":\"Curing Heart Disease, LLC\"},\"image\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/curingheartdisease\",\"https:\\\/\\\/x.com\\\/RMHDInc\",\"https:\\\/\\\/www.instagram.com\\\/rmhdinc\\\/\",\"https:\\\/\\\/www.youtube.com\\\/channel\\\/UCm8dh9c_D5RfJL7Z1f-yY4w\"],\"description\":\"Curing Heart Disease, LLC is an independent cardiovascular health education organization that publishes evidence-based articles, videos, podcasts, and educational tools about cardiovascular disease prevention, lipid science, nutrition, exercise, and related health topics.\",\"founder\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"foundingPerson\":{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\"},\"knowsAbout\":[\"Cardiovascular health\",\"Cardiovascular disease prevention\",\"Heart disease education\",\"Nutrition\",\"Exercise\",\"Lipid science\",\"Atherosclerosis\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#\\\/schema\\\/person\\\/1468f3f6d05d6929d0583938c1236e53\",\"name\":\"Peter Megdal, PhD\",\"url\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\",\"givenName\":\"Peter\",\"familyName\":\"Megdal\",\"honorificSuffix\":\"PhD\",\"jobTitle\":\"Nutrition Researcher and Cardiovascular Health Educator\",\"description\":\"Peter Megdal, PhD, is a nutrition researcher, cardiovascular health educator, published researcher, and longtime competitive cyclist. He earned a PhD in nutrition from the University of Massachusetts and publishes evidence-based cardiovascular health education through Curing Heart Disease.\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/peters-story\\\/\"},\"worksFor\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"affiliation\":{\"@id\":\"https:\\\/\\\/www.curingheartdisease.com\\\/#organization\"},\"alumniOf\":{\"@type\":\"CollegeOrUniversity\",\"name\":\"University of Massachusetts\"},\"knowsAbout\":[\"Nutrition\",\"Cardiovascular health education\",\"Cardiovascular disease prevention\",\"Lipid science\",\"Exercise physiology\",\"Scientific research\"],\"sameAs\":[\"https:\\\/\\\/www.curingheartdisease.com\\\/author\\\/peter-megdal\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/peter-megdal-56075a2\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"El avance del colesterol: de las pastillas diarias a las inyecciones dos veces al a\u00f1o - La principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.curingheartdisease.com\/es\/el-avance-del-colesterol-de-las-pastillas-diarias-a-las-inyecciones-dos-veces-al-ano\/","og_locale":"es_ES","og_type":"article","og_title":"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots - The Premiere Heart Health Education Platform","og_description":"Atherosclerotic cardiovascular disease (ASCVD) remains the leading global cause of mortality despite major advances in acute care. Modern preventive cardiology increasingly recognizes apolipoprotein B (ApoB)\u2013containing lipoproteins as the necessary and causal drivers of atherosclerosis.","og_url":"https:\/\/www.curingheartdisease.com\/es\/el-avance-del-colesterol-de-las-pastillas-diarias-a-las-inyecciones-dos-veces-al-ano\/","og_site_name":"The Premiere Heart Health Education Platform","article_publisher":"https:\/\/www.facebook.com\/curingheartdisease","article_published_time":"2026-02-24T15:21:47+00:00","article_modified_time":"2026-07-16T14:53:18+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg","type":"image\/jpeg"}],"author":"Peter Megdal PhD","twitter_card":"summary_large_image","twitter_creator":"@RMHDInc","twitter_site":"@RMHDInc","twitter_misc":{"Escrito por":"Peter Megdal PhD","Tiempo de lectura":"6 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#article","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/"},"author":{"name":"Peter Megdal PhD","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53"},"headline":"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots","datePublished":"2026-02-24T15:21:47+00:00","dateModified":"2026-07-16T14:53:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/"},"wordCount":1075,"publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg","articleSection":["Lipids, Medications and Testing","Medications and Treatments","Plaque, Arteries and Disease","Regression and Reversal"],"inLanguage":"es-AR"},{"@type":"WebPage","@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/","url":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/","name":"El avance del colesterol: de las pastillas diarias a las inyecciones dos veces al a\u00f1o - La principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","isPartOf":{"@id":"https:\/\/www.curingheartdisease.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#primaryimage"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#primaryimage"},"thumbnailUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg","datePublished":"2026-02-24T15:21:47+00:00","dateModified":"2026-07-16T14:53:18+00:00","breadcrumb":{"@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#breadcrumb"},"inLanguage":"es-AR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/"]}]},{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#primaryimage","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/02\/post-image-34.jpg","width":1200,"height":630},{"@type":"BreadcrumbList","@id":"https:\/\/www.curingheartdisease.com\/the-cholesterol-breakthrough-from-daily-pills-to-twice-a-year-shots\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.curingheartdisease.com\/"},{"@type":"ListItem","position":2,"name":"The Cholesterol Breakthrough: From Daily Pills to Twice-a-Year Shots"}]},{"@type":"WebSite","@id":"https:\/\/www.curingheartdisease.com\/#website","url":"https:\/\/www.curingheartdisease.com\/","name":"La principal plataforma de educaci\u00f3n sobre la salud card\u00edaca","description":"Poner a disposici\u00f3n del p\u00fablico la informaci\u00f3n m\u00e1s avanzada sobre c\u00f3mo revertir la enfermedad card\u00edaca. Esta es una organizaci\u00f3n basada en la evidencia que utiliza la mejor ciencia disponible, incluyendo dieta, ejercicio, medicamentos y otros recursos para combatir de la mejor manera esta enfermedad.","publisher":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.curingheartdisease.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-AR"},{"@type":"Organization","@id":"https:\/\/www.curingheartdisease.com\/#organization","name":"Curing Heart Disease, LLC","url":"https:\/\/www.curingheartdisease.com\/","logo":{"@type":"ImageObject","inLanguage":"es-AR","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","contentUrl":"https:\/\/www.curingheartdisease.com\/wp-content\/uploads\/2026\/06\/cropped-Curing-Heart-icon-red.png","width":512,"height":512,"caption":"Curing Heart Disease, LLC"},"image":{"@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/curingheartdisease","https:\/\/x.com\/RMHDInc","https:\/\/www.instagram.com\/rmhdinc\/","https:\/\/www.youtube.com\/channel\/UCm8dh9c_D5RfJL7Z1f-yY4w"],"description":"Curing Heart Disease, LLC es una organizaci\u00f3n independiente de educaci\u00f3n sobre salud cardiovascular que publica art\u00edculos, videos, p\u00f3dcasts y herramientas educativas basados en evidencia cient\u00edfica sobre la prevenci\u00f3n de enfermedades cardiovasculares, la ciencia de los l\u00edpidos, la nutrici\u00f3n, el ejercicio y temas de salud relacionados.","founder":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"foundingPerson":{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD"},"knowsAbout":["Cardiovascular health","Cardiovascular disease prevention","Heart disease education","Nutrition","Exercise","Lipid science","Atherosclerosis"]},{"@type":"Person","@id":"https:\/\/www.curingheartdisease.com\/#\/schema\/person\/1468f3f6d05d6929d0583938c1236e53","name":"Peter Megdal, PhD","url":"https:\/\/www.curingheartdisease.com\/peters-story\/","givenName":"Peter","familyName":"Megdal","honorificSuffix":"PhD","jobTitle":"Nutrition Researcher and Cardiovascular Health Educator","description":"Peter Megdal, PhD es investigador en nutrici\u00f3n, educador en salud cardiovascular, autor de publicaciones cient\u00edficas y ciclista de competencia desde hace mucho tiempo. Obtuvo un doctorado en nutrici\u00f3n de la Universidad de Massachusetts y difunde informaci\u00f3n educativa sobre salud cardiovascular basada en la evidencia a trav\u00e9s de Curing Heart Disease.","mainEntityOfPage":{"@id":"https:\/\/www.curingheartdisease.com\/peters-story\/"},"worksFor":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"affiliation":{"@id":"https:\/\/www.curingheartdisease.com\/#organization"},"alumniOf":{"@type":"CollegeOrUniversity","name":"University of Massachusetts"},"knowsAbout":["Nutrition","Cardiovascular health education","Cardiovascular disease prevention","Lipid science","Exercise physiology","Scientific research"],"sameAs":["https:\/\/www.curingheartdisease.com\/author\/peter-megdal\/","https:\/\/www.linkedin.com\/in\/peter-megdal-56075a2\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/9520","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/comments?post=9520"}],"version-history":[{"count":16,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/9520\/revisions"}],"predecessor-version":[{"id":12102,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/posts\/9520\/revisions\/12102"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/media\/9532"}],"wp:attachment":[{"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/media?parent=9520"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/categories?post=9520"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.curingheartdisease.com\/es\/wp-json\/wp\/v2\/tags?post=9520"}],"curies":[{"name":"\u00a1Bien jugado!","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}